# What BARI-STEP found after bariatric surgery

- Article ID: research-155
- Product: GLP-1 SEMA (glp-1-sema-687, glp-1-sema-688)
- Canonical page: https://heritagebiolabs.com/research-library/articles/155-what-bari-step-found-after-bariatric-surgery
- Product collection: https://heritagebiolabs.com/research-library/products/glp-1-sema
- Product page: https://heritagebiolabs.com/product/glp-1-sema-687
- Product page: https://heritagebiolabs.com/product/glp-1-sema-688
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held together by peptide bonds. Some can activate receptors involved in glucose regulation and fullness. Semaglutide is a modified GLP-1 receptor agonist peptide. In the 2026 BARI-STEP trial, researchers tested whether it affected body weight in adults who had lost less weight than the study’s threshold after bariatric surgery. [1]

The investigators recruited adults at least a year after gastric bypass or sleeve gastrectomy. To enter this trial, participants had to have lost less than 20% of their body weight from the surgery. Seventy adults were assigned to semaglutide or placebo, and both groups received the trial’s lifestyle support. The eligibility rule describes the group that investigators wanted to study. It does not turn the percentage into a universal definition of whether a surgery worked for an individual patient. [1]

At 68 weeks, estimated mean weight change was −18.0% in the semaglutide group and +0.4% in the placebo group. The adjusted difference between groups was approximately −19.2 percentage points. The authors also assessed measures related to metabolism and quality of life. Sixty-three of the 70 randomized participants were included in the analysis set described in the paper. The study design and the participants represented in the analysis are part of the context for interpreting the size and precision of the weight result. [1]

The research team documented adverse events and reported eight serious events, including one suspected unexpected serious adverse reaction, across the study. The paper did not identify a new overall safety concern specific to the enrolled group. With 70 participants, the study can describe the events it observed. Its size limits the conclusions available about rare events. The data also reflect two specific types of surgery, so evidence about people after another operation or with other patterns of weight change would require its own assessment. [1]

A placebo-controlled study in people after bariatric surgery answers a question that general obesity trials cannot answer on their own. It evaluates the intervention in a population with a specific medical history and starts measurement after that surgery. The change measured over the following 68 weeks belongs to this trial. It should be read alongside what the FDA label says about the approved product and with the study’s particular eligibility and follow-up in view. [1, 2]

## Sources

1. C. Stanley et al. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. Nature Medicine (publication 2026-05-22). <https://pubmed.ncbi.nlm.nih.gov/42174253/>
2. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Drugs@FDA (publication 2026-06). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 031 - GLOW 2 Blend and GLP-1 SEMA.docx; article 155; content SHA-256 3ca49228eaee1f680d26541cfb98a27ff6e768dc22ddea4c1eef878531fcc0a7.
